左卡尼汀联合促红素及蔗糖铁治疗肾性贫血疗效分析  

Clinical Effect Analysis of L-carnitine Combined with Erythropoietin and Ferralia in the Treatment of Renal Anemia

作　　者：李鸽[1] 肖伟[1] 桂永丰[1] 任泽银[1] 

机构地区：[1]常德市第一人民医院,湖南常德415000

出　　处：《中外医学研究》2016年第7期3-5,共3页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:观察左卡尼汀联合促红细胞生成素(EPO)及蔗糖铁治疗尿毒症血液透析患者肾性贫血的疗效。方法:将64例确诊为尿毒症行血液透析肾性贫血患者随机分成治疗组和对照组,每组32例。对照组注射EPO及蔗糖铁,治疗组在对照组的基础上加用左卡尼汀,疗程12周。分别于第4周、第8周、第12周测定两组患者的血红蛋白(Hb)、红细胞压积(Hct)、铁蛋白(SF)和转铁蛋白饱和度(TSAT)。并观察治疗过程中的不良反应。结果:治疗组Hb、Hct、SF、TSAT均高于对照组和治疗前(P<0.05),治疗组EPO用量和高血压发生率均较对照组少(P<0.05),治疗组患者治疗疗效显著高于对照组(P<0.05)。结论:左卡尼汀联合促红细胞生成素及蔗糖铁能显著提高尿毒症血液透析患者贫血的疗效,同时左卡尼汀能减少促红细胞生成素的用量,降低高血压的发生率。Objective：To observe the clinical effect of L-carnitine combined with erythropoietin（EPO） and ferralia in uremic patients with renal anemia.Method：64 hemodialysis patients in uremic patients with renal anemia were randomly divided into two groups,32 cases in each group.The control group were treated with EPO and ferralia.The treatment group was injected with L-carnitine additionally on base of the control group.Hemoglobin（Hb）,hematocrit（Hct）,serum ferritin（SF）,transferrin saturation（TSAT） were observed before and during the treatment,and EPO dosage was compared during 12 weeks in patients of two groups.Result：After 12 weeks of treatment,the Hb,Hct,SF,TSAT were higher in the treatment group than the control group（P〈0.05）,meanwhile,the dosage of EPO and the incidence of hypertension in the treatment group were lower than the control group（P〈0.05）.The treatment group patients curative effect was significantly higher than that of the control group（P〈0.05）.Conclusion：L-carnitine combined with EPO and ferralia may increase the effect of renal anemia,while reduce the dosage of EPO and its adverse effects.

关 键 词：左卡尼汀 促红细胞生成素 蔗糖铁 肾性贫血 

分 类 号：R692.5[医药卫生—泌尿科学]